henhaobio
Sign in

Communications BiologyBioengineeringPeer-reviewed journal article

A metabolic-dysfunction associated steatotic liver acinus biomimetic induces pancreatic islet dysfunction in a coupled microphysiology system

Julio AlemaniD, K. RavikumariD, Connor WiegandiD, Mark E. SchurdakiD, Lawrence A. VernettiiD, Dillon C. GavlockiD, Celeste E. Reese, Richard DeBiasio, Greg LaRocca, Yulder Daniel Angarita, Albert GoughiD, Alejandro Soto–GutiérreziD, Jaideep BehariiD, Vijay K. YechooriD, Mark T. MiedeliD, Andrew M. SterniD, Ipsita BanerjeeiD, D. Lansing TayloriD

PDFDOIPreprint

Abstract

Preclinical and clinical studies suggest that lipid-induced hepatic insulin resistance is a primary defect that predisposes to dysfunction in pancreatic islets, implicating a perturbed liver-pancreas axis underlying the comorbidity of T2DM and MASLD. To investigate this hypothesis, we developed a human biomimetic microphysiological system (MPS) coupling our vascularized liver acinus MPS (vLAMPS) with primary islets on a chip (PANIS) enabling MASLD progression and islet dysfunction to be quantitatively assessed. The modular design of this system (vLAMPS-PANIS) allows intra-organ and inter-organ dysregulation to be deconvoluted. When compared to normal fasting (NF) conditions, under early metabolic syndrome (EMS) conditions, the standalone vLAMPS exhibited characteristics of early stage MASLD, while no significant differences were observed in the standalone PANIS. In contrast, with EMS, the coupled vLAMPS-PANIS exhibited a perturbed islet-specific secretome and a significantly dysregulated glucose stimulated insulin secretion (GSIS) response implicating direct signaling from the dysregulated liver acinus to the islets. Correlations between several pairs of a vLAMPS-derived and a PANIS-derived secreted factors were significantly altered under EMS, as compared to NF conditions, mechanistically connecting MASLD and T2DM associated hepatic factors with islet-derived GLP-1 synthesis and regulation. Since vLAMPS-PANIS is compatible with patient-specific iPSCs, this platform represents an important step towards addressing patient heterogeneity, identifying complex disease mechanisms, and advancing precision medicine.

Citations
12
FWCI
3.31
Field percentile
top 7%

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISAleman '26Rigal '23Hellen '26Xia '24Casas '21Tevonian '26
81% semantic matchBioengineering
Julio Aleman, Lawrence A. Vernetti, Mark E. Schurdak+6 more·BMC Biotechnology·Apr 30, 2026· 1 citations